Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2013

View Archived Issues

Novel aminoglycoside antibiotic shows anti-MRSA activity with reduced nephrotoxicity

CETP inhibitors for the treatment of atherosclerosis

Smallpox vaccine CJ-50300 safe in phase III trial

Novan compares activity of Nitricil compounds against Staphylococcus aureus

Acacia Pharma initiates phase III studies of APD-421 for PONV

Regado Biosciences begins phase III trial of pegnivacogin/anivamersen

PeptiDream licenses PDPS technology to Bristol-Myers Squibb

AGE receptors identified in human osteoarthritic cartilage

Agenus reports follow-on phase II data for brain cancer vaccine

Third review also recommends PreSERVE AMI study continuation

Repros Therapeutics reports Androxal study data

BioCryst awarded NIAID contract to combat Marburg virus hemorrhagic fever

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Profectus BioSciences begins phase I trial of HIV plasmid DNA vaccine

H3 Biomedicine and Selvita establish strategic collaboration in oncology

Compugen reports data on immune checkpoint protein CGEN-15049

Rottapharm patents novel orexin OX1 receptor antagonists

FORMA Therapeutics and Genentech disclose Nampt inhibitors

PIQUR Therapeutics plans phase I study of PQR-309

Takeda designs series of MetAP 2 inhibitors

Allergan synthesizes series of chemokine CCR2 receptor antagonists

ChemoCentryx regains rights to vercirnon from GlaxoSmithKline

Mitsubishi Tanabe Pharma acquires Medicago

CE mark granted to Abbott's FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...